Free Trial
NASDAQ:MGRM

Monogram Orthopaedics (MGRM) Stock Price, News & Analysis

$2.38
-0.11 (-4.42%)
(As of 10/23/2024 ET)

About Monogram Orthopaedics Stock (NASDAQ:MGRM)

Key Stats

Today's Range
$2.38
$2.49
50-Day Range
$2.30
$3.44
52-Week Range
$1.53
$4.90
Volume
42,978 shs
Average Volume
149,583 shs
Market Capitalization
$75.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Monogram Orthopaedics, Inc. is a leading medical device company specializing in developing and manufacturing innovative orthopedic solutions. The company, founded in 2016, is dedicated to transforming the landscape of orthopedic surgeries by providing personalized implants that optimize patient outcomes and improve surgical efficiency. The company is also developing a surgical robot to install these customized implants. Monogram Orthopaedics operates from its headquarters in Austin, Texas, with additional offices and manufacturing facilities in key medical hubs worldwide.

The mission of Monogram Orthopaedics is to revolutionize orthopedic care by advancing personalized solutions. By leveraging cutting-edge technologies and data analytics, the company aims to create implants tailored to each patient's unique anatomy, resulting in improved implant fit, reduced complications, and enhanced patient satisfaction. Monogram Orthopaedics envisions a future where orthopedic surgeries are streamlined, efficient, and deliver superior clinical outcomes.

Monogram Orthopaedics is led by a highly experienced and accomplished management team that brings a wealth of expertise to the medical device industry. At the company's helm is the co-founder, Mr. Benjamin Sexson, C.F.A., who serves as the Chairman, President, and Chief Executive Officer. With a solid background in finance and extensive leadership experience, Mr. Sexson has played a pivotal role in driving Monogram Orthopaedics' strategic direction and ensuring its continued growth and success. His leadership has been instrumental in shaping the company's vision and guiding it toward delivering innovative orthopedic solutions.

Monogram Orthopaedics operates in the highly competitive orthopedic medical device industry, characterized by rapid technological advancements and evolving patient expectations. Established players dominate the market, but Monogram Orthopaedics is carving out a niche by focusing on personalized solutions that optimize surgical outcomes.

The industry is witnessing a shift toward value-based care, emphasizing cost-effective treatments and improved patient experiences. Monogram Orthopaedics' personalized implants align with this industry trend, as they offer surgeons greater precision, reduce complications and contribute to shorter hospital stays and faster recoveries. Monogram Orthopaedics is at the forefront of innovation by leveraging data analytics and advanced imaging techniques, driving industry transformation.

Competitive advantages of Monogram Orthopaedics include its proprietary technology, strong industry relationships, and a culture of innovation. The company's personalized approach to orthopedic surgeries sets it apart from competitors, providing a unique value proposition to patients and healthcare providers. Monogram Orthopaedics' commitment to research and development ensures a steady pipeline of novel products, securing its competitive edge in the market.

Monogram Orthopaedics is well-positioned to capitalize on several growth opportunities within the orthopedic industry. One such opportunity lies in expanding its product portfolio to include personalized solutions for additional anatomical sites, such as the spine and shoulder. By leveraging its expertise and relationships, the company can capture a larger share of the orthopedic market and address a broader range of patient needs.

While Monogram Orthopaedics enjoys a strong market position and favorable growth prospects, it is not immune to the risks and challenges inherent in the industry. One significant risk is the potential for regulatory changes and compliance requirements. The medical device sector is subject to strict regulations and oversight, impacting product development timelines and market access. Monogram Orthopaedics must closely monitor regulatory developments and ensure compliance to mitigate any potential disruptions to its operations.

Another challenge is the intense competition within the orthopedic industry. Established players and new entrants constantly strive to develop innovative solutions, which could erode Monogram Orthopaedics' market share. The company must continue investing in research and development, focusing on technological advancements and clinical evidence to maintain its competitive edge.

Changes in healthcare policies and reimbursement models can significantly impact the demand and pricing of orthopedic devices. Monogram Orthopaedics should closely monitor healthcare trends and policy changes to effectively navigate reimbursement challenges and ensure the continued adoption of its personalized implant solutions.

Risk management strategies for Monogram Orthopaedics include diversification of its product portfolio, maintaining solid relationships with key opinion leaders, and staying at the forefront of technological advancements. The company can mitigate potential disruptions and sustain its growth trajectory by proactively addressing risks and challenges.

Monogram Orthopaedics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
11th Percentile Overall Score

MGRM MarketRank™: 

Monogram Orthopaedics scored higher than 11% of companies evaluated by MarketBeat, and ranked 952nd out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Monogram Orthopaedics are expected to decrease in the coming year, from ($0.45) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Monogram Orthopaedics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Monogram Orthopaedics is -7.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Monogram Orthopaedics has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Monogram Orthopaedics' valuation and earnings.
  • Percentage of Shares Shorted

    2.68% of the float of Monogram Orthopaedics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monogram Orthopaedics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monogram Orthopaedics has recently decreased by 26.48%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Monogram Orthopaedics does not currently pay a dividend.

  • Dividend Growth

    Monogram Orthopaedics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.68% of the float of Monogram Orthopaedics has been sold short.
  • Short Interest Ratio / Days to Cover

    Monogram Orthopaedics has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Monogram Orthopaedics has recently decreased by 26.48%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 3 people have searched for MGRM on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • MarketBeat Follows

    Only 7 people have added Monogram Orthopaedics to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Monogram Orthopaedics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    32.10% of the stock of Monogram Orthopaedics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 0.45% of the stock of Monogram Orthopaedics is held by institutions.

  • Read more about Monogram Orthopaedics' insider trading history.
Receive MGRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monogram Orthopaedics and its competitors with MarketBeat's FREE daily newsletter.

MGRM Stock News Headlines

Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
MGRM Stock Earnings: Monogram Technologies Misses EPS for Q2 2024
See More Headlines

MGRM Stock Analysis - Frequently Asked Questions

Monogram Orthopaedics' stock was trading at $3.44 at the beginning of the year. Since then, MGRM stock has decreased by 30.8% and is now trading at $2.38.
View the best growth stocks for 2024 here
.

Monogram Orthopaedics, Inc. (NASDAQ:MGRM) issued its earnings results on Thursday, August, 15th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02.

Monogram Orthopaedics (MGRM) raised $17 million in an initial public offering (IPO) on Thursday, May 18th 2023. The company issued 2,374,641 shares at a price of $7.25 per share.

Shares of MGRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Monogram Orthopaedics investors own include Mullen Automotive (MULN), Faraday Future Intelligent Electric (FFIE), Plug Power (PLUG), AMC Entertainment (AMC), CXApp (CXAI), Draganfly (DPRO) and Palantir Technologies (PLTR).

Company Calendar

Last Earnings
8/15/2024
Today
10/24/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:MGRM
Fax
N/A
Employees
28
Year Founded
N/A

Profitability

Net Income
$-13,740,000.00
Pretax Margin
-3,203.84%

Debt

Sales & Book Value

Annual Sales
$364,999.00
Book Value
$0.43 per share

Miscellaneous

Free Float
21,526,000
Market Cap
$75.37 million
Optionable
Not Optionable
Beta
2.22
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:MGRM) was last updated on 10/24/2024 by MarketBeat.com Staff
From Our Partners